Hereditary Amyloidosis Treatment Market

Future Market Insights

Key Insight

The hereditary amyloidosis treatment market is projected to grow from USD 11.6 billion in 2025 to USD 48.2 billion by 2035, at a CAGR of 15.3%. ATTR amyloidosis will dominate with a 64.1% market share, while source treatment will lead the treatment type segment with a 57.6% share.

September 15, 2025

Anurag Sharma

275 Pages

Cite this Report

Hereditary Amyloidosis Treatment Market

https://www.futuremarketinsights.com/reports/hereditary-amyloidosis-treatment-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Akcea Therapeutics
Alnylam Pharmaceuticals
Eidos Therapeutics
Ionis Pharmaceuticals
The Vanguard Group
Prothena Corporation

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Hereditary Amyloidosis Treatment Market

Key Players

Similar Industry Reports